COVID-19医薬品 - 世界市場シェア・ランキング、全体売上高・需要予測 2024-2030COVID-19 Medicine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 COVID-19医薬の世界市場は、2023年に100万米ドルの価値があると推定され、2024年から2030年の予測期間中に%のCAGRで2030年までに100万米ドルの再調整された規模になると予測されています。 COVID-19医薬の北米... もっと見る
※当ページの内容はウェブ更新時の情報です。
サマリーCOVID-19医薬の世界市場は、2023年に100万米ドルの価値があると推定され、2024年から2030年の予測期間中に%のCAGRで2030年までに100万米ドルの再調整された規模になると予測されています。COVID-19医薬の北米市場は、2023年に百万米ドルと評価され、2024年から2030年の予測期間中に%のCAGRで、2030年までに百万米ドルに達すると予測されています。 COVID-19医薬のアジア太平洋市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に%のCAGRで、2030年までに100万ドルに達するでしょう。 COVID-19医薬のヨーロッパ市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に%のCAGRで、2030年までに100万ドルに達するでしょう。 COVID-19医薬の世界主要企業は、Advanz Pharma、Kyung Poong、Mylan、Novartis、Sanofi、Apotex、Bayer、広州白雲山光華医薬、Ipca Laboratoriesなどである。2023年には、世界の大手5社が売上高で約 %のシェアを占めている。 レポートの範囲 本レポートは、COVID-19医薬の世界市場を包括的に紹介することを目的とし、COVID-19医薬の地域別・国別、タイプ別、用途別の分析とともに、総売上高、主要企業の市場シェア、ランキングに焦点を当てています。 COVID-19医薬の市場規模、推計、予測は、2023年を基準年として、2019年から2030年までの期間の履歴データと予測データを売上高(百万ドル)で提供します。定量分析および定性分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場での地位を分析し、COVID-19 Medicineに関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。 市場区分 企業別 アドバンツファーマ キョン・プーン マイラン ノバルティス サノフィ アポテックス バイエル 広州白雲山光華製薬 イプカ・ラボラトリーズ 四川サニーホープ ザイダス・カディラ テバ サンファーマ ライジング製薬 KPCグループ ブリストル研究所 上海中西三威 上海製薬 タイプ別セグメント 錠剤 注射剤 用途別セグメント 軽症患者 重症患者 その他 地域別 北米 米国 カナダ 欧州 ドイツ フランス イギリス イタリア ロシア アジア太平洋 中国 日本 韓国 中国 台湾 東南アジア インド ラテンアメリカ メキシコ ブラジル アルゼンチン 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 各章の概要 第1章:報告書のスコープ、世界の総市場規模を紹介。本章ではまた、市場力学、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。 第2章:COVID-19医薬メーカーの競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。 第3章:タイプ別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる市場セグメントのブルーオーシャン市場を見つけるのに役立つ。 第4章:用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。 第5章:地域レベルでのCOVID-19医薬品の収益。各地域の市場規模と発展潜在力を定量的に分析し、世界各国の市場発展、将来発展展望、市場空間、市場規模を紹介する。 第6章 COVID-19医薬品の国別売上高各国・地域のタイプ別、用途別のシグメイトデータを提供している。 第7章:主要企業のプロフィールを提供し、製品収益、粗利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介する。 第8章:産業の上流と下流を含む産業チェーンの分析。 第9章:結論 目次1 Market Overview1.1 COVID-19 Medicine Product Introduction 1.2 Global COVID-19 Medicine Market Size Forecast 1.3 COVID-19 Medicine Market Trends & Drivers 1.3.1 COVID-19 Medicine Industry Trends 1.3.2 COVID-19 Medicine Market Drivers & Opportunity 1.3.3 COVID-19 Medicine Market Challenges 1.3.4 COVID-19 Medicine Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global COVID-19 Medicine Players Revenue Ranking (2023) 2.2 Global COVID-19 Medicine Revenue by Company (2019-2024) 2.3 Key Companies COVID-19 Medicine Manufacturing Base Distribution and Headquarters 2.4 Key Companies COVID-19 Medicine Product Offered 2.5 Key Companies Time to Begin Mass Production of COVID-19 Medicine 2.6 COVID-19 Medicine Market Competitive Analysis 2.6.1 COVID-19 Medicine Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by COVID-19 Medicine Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 Medicine as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Tablet 3.1.2 Injection 3.2 Global COVID-19 Medicine Sales Value by Type 3.2.1 Global COVID-19 Medicine Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global COVID-19 Medicine Sales Value, by Type (2019-2030) 3.2.3 Global COVID-19 Medicine Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Patients With Mild Symptoms 4.1.2 Critically Ill 4.1.3 Other 4.2 Global COVID-19 Medicine Sales Value by Application 4.2.1 Global COVID-19 Medicine Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global COVID-19 Medicine Sales Value, by Application (2019-2030) 4.2.3 Global COVID-19 Medicine Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global COVID-19 Medicine Sales Value by Region 5.1.1 Global COVID-19 Medicine Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global COVID-19 Medicine Sales Value by Region (2019-2024) 5.1.3 Global COVID-19 Medicine Sales Value by Region (2025-2030) 5.1.4 Global COVID-19 Medicine Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America COVID-19 Medicine Sales Value, 2019-2030 5.2.2 North America COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe COVID-19 Medicine Sales Value, 2019-2030 5.3.2 Europe COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific COVID-19 Medicine Sales Value, 2019-2030 5.4.2 Asia Pacific COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America COVID-19 Medicine Sales Value, 2019-2030 5.5.2 South America COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa COVID-19 Medicine Sales Value, 2019-2030 5.6.2 Middle East & Africa COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions COVID-19 Medicine Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions COVID-19 Medicine Sales Value 6.3 United States 6.3.1 United States COVID-19 Medicine Sales Value, 2019-2030 6.3.2 United States COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030 6.3.3 United States COVID-19 Medicine Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe COVID-19 Medicine Sales Value, 2019-2030 6.4.2 Europe COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe COVID-19 Medicine Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China COVID-19 Medicine Sales Value, 2019-2030 6.5.2 China COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030 6.5.3 China COVID-19 Medicine Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan COVID-19 Medicine Sales Value, 2019-2030 6.6.2 Japan COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan COVID-19 Medicine Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea COVID-19 Medicine Sales Value, 2019-2030 6.7.2 South Korea COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea COVID-19 Medicine Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia COVID-19 Medicine Sales Value, 2019-2030 6.8.2 Southeast Asia COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia COVID-19 Medicine Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India COVID-19 Medicine Sales Value, 2019-2030 6.9.2 India COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030 6.9.3 India COVID-19 Medicine Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 Advanz Pharma 7.1.1 Advanz Pharma Profile 7.1.2 Advanz Pharma Main Business 7.1.3 Advanz Pharma COVID-19 Medicine Products, Services and Solutions 7.1.4 Advanz Pharma COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.1.5 Advanz Pharma Recent Developments 7.2 Kyung Poong 7.2.1 Kyung Poong Profile 7.2.2 Kyung Poong Main Business 7.2.3 Kyung Poong COVID-19 Medicine Products, Services and Solutions 7.2.4 Kyung Poong COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.2.5 Kyung Poong Recent Developments 7.3 Mylan 7.3.1 Mylan Profile 7.3.2 Mylan Main Business 7.3.3 Mylan COVID-19 Medicine Products, Services and Solutions 7.3.4 Mylan COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.3.5 Novartis Recent Developments 7.4 Novartis 7.4.1 Novartis Profile 7.4.2 Novartis Main Business 7.4.3 Novartis COVID-19 Medicine Products, Services and Solutions 7.4.4 Novartis COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.4.5 Novartis Recent Developments 7.5 Sanofi 7.5.1 Sanofi Profile 7.5.2 Sanofi Main Business 7.5.3 Sanofi COVID-19 Medicine Products, Services and Solutions 7.5.4 Sanofi COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.5.5 Sanofi Recent Developments 7.6 Apotex 7.6.1 Apotex Profile 7.6.2 Apotex Main Business 7.6.3 Apotex COVID-19 Medicine Products, Services and Solutions 7.6.4 Apotex COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.6.5 Apotex Recent Developments 7.7 Bayer 7.7.1 Bayer Profile 7.7.2 Bayer Main Business 7.7.3 Bayer COVID-19 Medicine Products, Services and Solutions 7.7.4 Bayer COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.7.5 Bayer Recent Developments 7.8 Guangzhou Baiyunshan Guanghua Pharmaceutical 7.8.1 Guangzhou Baiyunshan Guanghua Pharmaceutical Profile 7.8.2 Guangzhou Baiyunshan Guanghua Pharmaceutical Main Business 7.8.3 Guangzhou Baiyunshan Guanghua Pharmaceutical COVID-19 Medicine Products, Services and Solutions 7.8.4 Guangzhou Baiyunshan Guanghua Pharmaceutical COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.8.5 Guangzhou Baiyunshan Guanghua Pharmaceutical Recent Developments 7.9 Ipca Laboratories 7.9.1 Ipca Laboratories Profile 7.9.2 Ipca Laboratories Main Business 7.9.3 Ipca Laboratories COVID-19 Medicine Products, Services and Solutions 7.9.4 Ipca Laboratories COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.9.5 Ipca Laboratories Recent Developments 7.10 Sichuan Sunny Hope 7.10.1 Sichuan Sunny Hope Profile 7.10.2 Sichuan Sunny Hope Main Business 7.10.3 Sichuan Sunny Hope COVID-19 Medicine Products, Services and Solutions 7.10.4 Sichuan Sunny Hope COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.10.5 Sichuan Sunny Hope Recent Developments 7.11 Zydus Cadila 7.11.1 Zydus Cadila Profile 7.11.2 Zydus Cadila Main Business 7.11.3 Zydus Cadila COVID-19 Medicine Products, Services and Solutions 7.11.4 Zydus Cadila COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.11.5 Zydus Cadila Recent Developments 7.12 Teva 7.12.1 Teva Profile 7.12.2 Teva Main Business 7.12.3 Teva COVID-19 Medicine Products, Services and Solutions 7.12.4 Teva COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.12.5 Teva Recent Developments 7.13 Sun Pharma 7.13.1 Sun Pharma Profile 7.13.2 Sun Pharma Main Business 7.13.3 Sun Pharma COVID-19 Medicine Products, Services and Solutions 7.13.4 Sun Pharma COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.13.5 Sun Pharma Recent Developments 7.14 Rising Pharmaceutical 7.14.1 Rising Pharmaceutical Profile 7.14.2 Rising Pharmaceutical Main Business 7.14.3 Rising Pharmaceutical COVID-19 Medicine Products, Services and Solutions 7.14.4 Rising Pharmaceutical COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.14.5 Rising Pharmaceutical Recent Developments 7.15 KPC Group 7.15.1 KPC Group Profile 7.15.2 KPC Group Main Business 7.15.3 KPC Group COVID-19 Medicine Products, Services and Solutions 7.15.4 KPC Group COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.15.5 KPC Group Recent Developments 7.16 Bristol Laboratories 7.16.1 Bristol Laboratories Profile 7.16.2 Bristol Laboratories Main Business 7.16.3 Bristol Laboratories COVID-19 Medicine Products, Services and Solutions 7.16.4 Bristol Laboratories COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.16.5 Bristol Laboratories Recent Developments 7.17 Shanghai Zhongxisanwei 7.17.1 Shanghai Zhongxisanwei Profile 7.17.2 Shanghai Zhongxisanwei Main Business 7.17.3 Shanghai Zhongxisanwei COVID-19 Medicine Products, Services and Solutions 7.17.4 Shanghai Zhongxisanwei COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.17.5 Shanghai Zhongxisanwei Recent Developments 7.18 Shanghai Pharma 7.18.1 Shanghai Pharma Profile 7.18.2 Shanghai Pharma Main Business 7.18.3 Shanghai Pharma COVID-19 Medicine Products, Services and Solutions 7.18.4 Shanghai Pharma COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.18.5 Shanghai Pharma Recent Developments 8 Industry Chain Analysis 8.1 COVID-19 Medicine Industrial Chain 8.2 COVID-19 Medicine Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 COVID-19 Medicine Sales Model 8.5.2 Sales Channel 8.5.3 COVID-19 Medicine Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
SummaryThe global market for COVID-19 Medicine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030. Table of Contents1 Market Overview1.1 COVID-19 Medicine Product Introduction 1.2 Global COVID-19 Medicine Market Size Forecast 1.3 COVID-19 Medicine Market Trends & Drivers 1.3.1 COVID-19 Medicine Industry Trends 1.3.2 COVID-19 Medicine Market Drivers & Opportunity 1.3.3 COVID-19 Medicine Market Challenges 1.3.4 COVID-19 Medicine Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global COVID-19 Medicine Players Revenue Ranking (2023) 2.2 Global COVID-19 Medicine Revenue by Company (2019-2024) 2.3 Key Companies COVID-19 Medicine Manufacturing Base Distribution and Headquarters 2.4 Key Companies COVID-19 Medicine Product Offered 2.5 Key Companies Time to Begin Mass Production of COVID-19 Medicine 2.6 COVID-19 Medicine Market Competitive Analysis 2.6.1 COVID-19 Medicine Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by COVID-19 Medicine Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 Medicine as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Tablet 3.1.2 Injection 3.2 Global COVID-19 Medicine Sales Value by Type 3.2.1 Global COVID-19 Medicine Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global COVID-19 Medicine Sales Value, by Type (2019-2030) 3.2.3 Global COVID-19 Medicine Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Patients With Mild Symptoms 4.1.2 Critically Ill 4.1.3 Other 4.2 Global COVID-19 Medicine Sales Value by Application 4.2.1 Global COVID-19 Medicine Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global COVID-19 Medicine Sales Value, by Application (2019-2030) 4.2.3 Global COVID-19 Medicine Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global COVID-19 Medicine Sales Value by Region 5.1.1 Global COVID-19 Medicine Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global COVID-19 Medicine Sales Value by Region (2019-2024) 5.1.3 Global COVID-19 Medicine Sales Value by Region (2025-2030) 5.1.4 Global COVID-19 Medicine Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America COVID-19 Medicine Sales Value, 2019-2030 5.2.2 North America COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe COVID-19 Medicine Sales Value, 2019-2030 5.3.2 Europe COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific COVID-19 Medicine Sales Value, 2019-2030 5.4.2 Asia Pacific COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America COVID-19 Medicine Sales Value, 2019-2030 5.5.2 South America COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa COVID-19 Medicine Sales Value, 2019-2030 5.6.2 Middle East & Africa COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions COVID-19 Medicine Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions COVID-19 Medicine Sales Value 6.3 United States 6.3.1 United States COVID-19 Medicine Sales Value, 2019-2030 6.3.2 United States COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030 6.3.3 United States COVID-19 Medicine Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe COVID-19 Medicine Sales Value, 2019-2030 6.4.2 Europe COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe COVID-19 Medicine Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China COVID-19 Medicine Sales Value, 2019-2030 6.5.2 China COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030 6.5.3 China COVID-19 Medicine Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan COVID-19 Medicine Sales Value, 2019-2030 6.6.2 Japan COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan COVID-19 Medicine Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea COVID-19 Medicine Sales Value, 2019-2030 6.7.2 South Korea COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea COVID-19 Medicine Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia COVID-19 Medicine Sales Value, 2019-2030 6.8.2 Southeast Asia COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia COVID-19 Medicine Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India COVID-19 Medicine Sales Value, 2019-2030 6.9.2 India COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030 6.9.3 India COVID-19 Medicine Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 Advanz Pharma 7.1.1 Advanz Pharma Profile 7.1.2 Advanz Pharma Main Business 7.1.3 Advanz Pharma COVID-19 Medicine Products, Services and Solutions 7.1.4 Advanz Pharma COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.1.5 Advanz Pharma Recent Developments 7.2 Kyung Poong 7.2.1 Kyung Poong Profile 7.2.2 Kyung Poong Main Business 7.2.3 Kyung Poong COVID-19 Medicine Products, Services and Solutions 7.2.4 Kyung Poong COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.2.5 Kyung Poong Recent Developments 7.3 Mylan 7.3.1 Mylan Profile 7.3.2 Mylan Main Business 7.3.3 Mylan COVID-19 Medicine Products, Services and Solutions 7.3.4 Mylan COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.3.5 Novartis Recent Developments 7.4 Novartis 7.4.1 Novartis Profile 7.4.2 Novartis Main Business 7.4.3 Novartis COVID-19 Medicine Products, Services and Solutions 7.4.4 Novartis COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.4.5 Novartis Recent Developments 7.5 Sanofi 7.5.1 Sanofi Profile 7.5.2 Sanofi Main Business 7.5.3 Sanofi COVID-19 Medicine Products, Services and Solutions 7.5.4 Sanofi COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.5.5 Sanofi Recent Developments 7.6 Apotex 7.6.1 Apotex Profile 7.6.2 Apotex Main Business 7.6.3 Apotex COVID-19 Medicine Products, Services and Solutions 7.6.4 Apotex COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.6.5 Apotex Recent Developments 7.7 Bayer 7.7.1 Bayer Profile 7.7.2 Bayer Main Business 7.7.3 Bayer COVID-19 Medicine Products, Services and Solutions 7.7.4 Bayer COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.7.5 Bayer Recent Developments 7.8 Guangzhou Baiyunshan Guanghua Pharmaceutical 7.8.1 Guangzhou Baiyunshan Guanghua Pharmaceutical Profile 7.8.2 Guangzhou Baiyunshan Guanghua Pharmaceutical Main Business 7.8.3 Guangzhou Baiyunshan Guanghua Pharmaceutical COVID-19 Medicine Products, Services and Solutions 7.8.4 Guangzhou Baiyunshan Guanghua Pharmaceutical COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.8.5 Guangzhou Baiyunshan Guanghua Pharmaceutical Recent Developments 7.9 Ipca Laboratories 7.9.1 Ipca Laboratories Profile 7.9.2 Ipca Laboratories Main Business 7.9.3 Ipca Laboratories COVID-19 Medicine Products, Services and Solutions 7.9.4 Ipca Laboratories COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.9.5 Ipca Laboratories Recent Developments 7.10 Sichuan Sunny Hope 7.10.1 Sichuan Sunny Hope Profile 7.10.2 Sichuan Sunny Hope Main Business 7.10.3 Sichuan Sunny Hope COVID-19 Medicine Products, Services and Solutions 7.10.4 Sichuan Sunny Hope COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.10.5 Sichuan Sunny Hope Recent Developments 7.11 Zydus Cadila 7.11.1 Zydus Cadila Profile 7.11.2 Zydus Cadila Main Business 7.11.3 Zydus Cadila COVID-19 Medicine Products, Services and Solutions 7.11.4 Zydus Cadila COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.11.5 Zydus Cadila Recent Developments 7.12 Teva 7.12.1 Teva Profile 7.12.2 Teva Main Business 7.12.3 Teva COVID-19 Medicine Products, Services and Solutions 7.12.4 Teva COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.12.5 Teva Recent Developments 7.13 Sun Pharma 7.13.1 Sun Pharma Profile 7.13.2 Sun Pharma Main Business 7.13.3 Sun Pharma COVID-19 Medicine Products, Services and Solutions 7.13.4 Sun Pharma COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.13.5 Sun Pharma Recent Developments 7.14 Rising Pharmaceutical 7.14.1 Rising Pharmaceutical Profile 7.14.2 Rising Pharmaceutical Main Business 7.14.3 Rising Pharmaceutical COVID-19 Medicine Products, Services and Solutions 7.14.4 Rising Pharmaceutical COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.14.5 Rising Pharmaceutical Recent Developments 7.15 KPC Group 7.15.1 KPC Group Profile 7.15.2 KPC Group Main Business 7.15.3 KPC Group COVID-19 Medicine Products, Services and Solutions 7.15.4 KPC Group COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.15.5 KPC Group Recent Developments 7.16 Bristol Laboratories 7.16.1 Bristol Laboratories Profile 7.16.2 Bristol Laboratories Main Business 7.16.3 Bristol Laboratories COVID-19 Medicine Products, Services and Solutions 7.16.4 Bristol Laboratories COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.16.5 Bristol Laboratories Recent Developments 7.17 Shanghai Zhongxisanwei 7.17.1 Shanghai Zhongxisanwei Profile 7.17.2 Shanghai Zhongxisanwei Main Business 7.17.3 Shanghai Zhongxisanwei COVID-19 Medicine Products, Services and Solutions 7.17.4 Shanghai Zhongxisanwei COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.17.5 Shanghai Zhongxisanwei Recent Developments 7.18 Shanghai Pharma 7.18.1 Shanghai Pharma Profile 7.18.2 Shanghai Pharma Main Business 7.18.3 Shanghai Pharma COVID-19 Medicine Products, Services and Solutions 7.18.4 Shanghai Pharma COVID-19 Medicine Revenue (US$ Million) & (2019-2024) 7.18.5 Shanghai Pharma Recent Developments 8 Industry Chain Analysis 8.1 COVID-19 Medicine Industrial Chain 8.2 COVID-19 Medicine Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 COVID-19 Medicine Sales Model 8.5.2 Sales Channel 8.5.3 COVID-19 Medicine Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(通信・IT)の最新刊レポート
QYResearch社の新技術分野での最新刊レポート
本レポートと同じKEY WORD(demand forecast)の最新刊レポートよくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/14 10:27 156.77 円 166.04 円 201.95 円 |